GO
Loading...

Gilead Sciences Inc

More

  • Lightning Round: Good stock with a good yield Wednesday, 17 Dec 2014 | 6:57 PM ET

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Midday Glance: Biotechnology companies Wednesday, 17 Dec 2014 | 1:17 PM ET

    Amgen Inc. rose $1.41 or. 9 percent, to $160.85. Biogen Idec rose $2.00 or. 6 percent, to $327.13. Celgene Corp. rose$. 63 or. 6 percent, to $110.72.

  • Early Glance: Biotechnology companies Wednesday, 17 Dec 2014 | 10:16 AM ET

    Amgen Inc. rose $1.19 or. 7 percent, to $160.63. Biogen Idec fell$. 02 or percent, to $325.11. Celgene Corp. rose$. 26 or. 2 percent, to $110.35.

  • Final Glance: Biotechnology companies Tuesday, 16 Dec 2014 | 6:41 PM ET

    Amgen Inc. fell$. 16 or. 1 percent, to $159.44. Biogen Idec fell $10.67 or 3.2 percent, to $325.13. Celgene Corp. fell $1.79 or 1.6 percent, to $110.09.

  • Midday Glance: Biotechnology companies Tuesday, 16 Dec 2014 | 1:20 PM ET

    Amgen Inc. rose $2.63 or 1.6 percent, to $162.23. Biogen Idec fell $2.99 or. 9 percent, to $332.81. Celgene Corp. rose$. 30 or. 3 percent, to $112.18.

  • Early Glance: Biotechnology companies Tuesday, 16 Dec 2014 | 10:20 AM ET

    Amgen Inc. rose$. 39 or. 2 percent, to $159.99. Biogen Idec rose$. 70 or. 2 percent, to $336.50. Celgene Corp. fell $1.53 or 1.4 percent, to $110.35.

  • Gilead sued over 'exorbitant' hepatitis C drug prices Wednesday, 10 Dec 2014 | 3:55 PM ET

    Dec 10- Philadelphia's transportation authority has filed a class action lawsuit accusing Gilead Sciences Inc of charging "exorbitant" prices for its blockbuster hepatitis C drug Sovaldi. The lawsuit, filed Tuesday in federal court in Philadelphia by the Southeastern Pennsylvania Transportation Authority, seeks an unspecified amount of money damages.

  • Gilead sued over pricing of hepatitis C drug Wednesday, 10 Dec 2014 | 3:37 PM ET

    Philadelphia's transit agency has filed a lawsuit against Gilead Sciences challenging the "exorbitant pricing" of its hepatitis C drug Sovaldi.

  • Retail investors try to catch bottom in oil Monday, 8 Dec 2014 | 12:00 PM ET
    Workers change a drill pipe on the Laurus oil drilling rig operated by Petroleos Mexicans (Pemex) in the Ku-Maloob-Zaap oilfield at Campeche Bay off the coast of Ciudad del Carmen, Mexico.

    Small investors loaded up on shares of energy stocks last month amid an epic decline of 40 percent in the price of oil from a recent high in July.

  • Lightning Round: Time to buy buy buy for 2015 Thursday, 4 Dec 2014 | 6:50 PM ET

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Cramer’s big discovery under the market's hood Wednesday, 3 Dec 2014 | 6:16 PM ET

    Jim Cramer takes a close look under the market's hood and makes a big discovery that could impact your portfolio.

  • Trader on the floor of the New York Stock Exchange.

    Some of Monday's midday movers:

  • Bristol-Myers said it had initially sought permission from the U.S. Food and Drug Administration to market the drug, a so-called NS5A inhibitor, in combination with asunaprevir, one of the New York- based company's experimental medicines. But Bristol-Myers abandoned its U.S. marketing application for asunaprevir in October because of potential...

  • Lightning Round: Do not own this Monday, 24 Nov 2014 | 6:54 PM ET

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Hedge funds playing buy-and-hold, and losing Monday, 24 Nov 2014 | 10:54 AM ET
    Pedestrians pass in front of an Apple store in New York.

    Hedge funds aren't changing their stock holdings much despite poor performance compared with the broader stock market.

  • How to get cancer drugs to kids: A mother's take Friday, 21 Nov 2014 | 6:00 AM ET
    The Froman family, including Nancy Goodman, Mike Froman, and kids Ben and Sarah. They hold a photo of Jacob, who died of medulloblastoma, a rare form of brain cancer, at age 10.

    Kids facing cancer need access to promising — albeit unapproved — drugs, say these parents, who have faced the battle with their children firsthand.

  • Nov 20- Global pharmaceutical spending will break the trillion dollar mark in 2014, driven by high prices in the United States for novel treatments such as Gilead Sciences Inc's Sovaldi for hepatitis C and new cancer drugs, according to a study released on Thursday. Total spending on drugs will hit $1.06 trillion, an increase of 7 percent over 2013 levels,...

  • Actavis Plc, Gilead Sciences and other biotechs were among the biggest drivers, a day after Allergan agreed to be bought by Actavis. Shares of Actavis were up 8.7 percent at $269.60, helped by bullish analyst notes, while Gilead's stock rose 3.3 percent to $103.71 percent. "A little bit of a risk trade is coming back on, and those are the areas for the M&A," said Uri...

  • Actavis Plc, Gilead Sciences, Celgene and other biotech names were among the S&P 500' s biggest drivers, a day after Allergan agreed to be bought by Actavis. The S&P health care index was up 1.6 percent, while shares of Actavis were up 8.3 percent, Gilead's rose 3.3 percent and shares of Celgene were up 2.4 percent. Helping Actavis were bullish analyst notes.

  • Midday movers: FibroGen, Google, McDonald's & more Friday, 14 Nov 2014 | 1:12 PM ET

    Some of Friday's midday movers: